Neuropediatrics 2019; 50(06): 400-403
DOI: 10.1055/s-0039-1695786
Short Communication
Georg Thieme Verlag KG Stuttgart · New York

Cannabidiol Interacts Significantly with Everolimus—Report of a Patient with Tuberous Sclerosis Complex

Adelheid Wiemer-Kruel
1   Clinic for Children and Adolescents, Epilepsy Center Kork, Tuberous Sclerosis Center, Kehl-Kork, Germany
,
Brigitte Stiller
2   Department of Congenital Heart Disease and Pediatric Cardiology, University Heart Centre Freiburg Bad Krozingen, University of Freiburg, Germany
3   Medical faculty of the University of Freiburg, University of Freiburg, Germany
,
Thomas Bast
1   Clinic for Children and Adolescents, Epilepsy Center Kork, Tuberous Sclerosis Center, Kehl-Kork, Germany
3   Medical faculty of the University of Freiburg, University of Freiburg, Germany
› Author Affiliations
Further Information

Publication History

15 May 2019

16 July 2019

Publication Date:
20 September 2019 (online)

Abstract

A 6.5-year-old female patient with a TSC2 mutation had been given everolimus (EVE) for 3 years for pharmacoresistant focal epilepsy and for life-threatening, severe ventricular dysrhythmia. EVE had been started with daily dose of 0.15 mg/kg/day and was increased up to 0.6 mg/kg/day. Target blood trough levels of around 9 µg/L had been documented. Although EVE therapy revealed no effect on seizure activity, cardiac rhythm normalized completely. Thus, EVE was reduced to a dose of 0.3 mg/kg/day leading to stable blood trough levels of 4 to 5 µg/L. Due to refractory tonic seizures with a frequency of 1 to 4 per day, we initiated cannabidiol (CBD) treatment, raising it to a daily dose of 200 mg. After 6 weeks, the EVE blood trough levels rose to 12.0 µg/L. Although we halved the EVE dose, her EVE blood trough level continued increasing up to 16.0 µg/L.

The CBD dose was increased to 500 mg/day (20.4 g/kg/day), but EEG parameters and seizures failed to respond. Serum concentrations of EVE were unstable under the co-medication with CBD. Depending on the CBD dose, they varied between 1.7 and 12.3 µg/L, while EVE was always administered at the same dose.

Although never before reported, CBD and EVE appear to interact, due to the metabolic pathway through CYP 450 3A4. Although we detected no side effects in our patient, we strongly recommend drug monitoring using the combination of CBD with EVE to prevent harmful overdosing.

 
  • References

  • 1 Franz DN, Bissler JJ, McCormack FX. Tuberous sclerosis complex: neurological, renal and pulmonary manifestations. Neuropediatrics 2010; 41 (05) 199-208
  • 2 Curatolo P, Bombardieri R, Jozwiak S. Tuberous sclerosis. Lancet 2008; 372 (9639): 657-668
  • 3 Dahdah N. Everolimus for the treatment of tuberous sclerosis complex-related cardiac rhabdomyomas in pediatric patients. J Pediatr 2017; 190: 21-26.e7
  • 4 Castro-Monsalve J, Alvarado-Socarras JL, Mantilla KA, Forero L, Moreno A, Prada CE. Cardiac rhabdomyomas in tuberous sclerosis complex. J Pediatr 2018; 192: 264-264.e1
  • 5 Hinton RB, Prakash A, Romp RL, Krueger DA, Knilans TK. ; International Tuberous Sclerosis Consensus Group. Cardiovascular manifestations of tuberous sclerosis complex and summary of the revised diagnostic criteria and surveillance and management recommendations from the International Tuberous Sclerosis Consensus Group. J Am Heart Assoc 2014; 3 (06) e001493
  • 6 Devinsky O, Cross JH, Laux L. , et al; Cannabidiol in Dravet Syndrome Study Group. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med 2017; 376 (21) 2011-2020
  • 7 Devinsky O, Patel AD, Cross JH. , et al; GWPCARE3 Study Group. Effect of cannabidiol on drop seizures in the Lennox-Gastaut syndrome. N Engl J Med 2018; 378 (20) 1888-1897
  • 8 Hess EJ, Moody KA, Geffrey AL. , et al. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex. Epilepsia 2016; 57 (10) 1617-1624
  • 9 Nickels K. Cannabidiol in patients with intractable epilepsy due to TSC: a possible medication but not a miracle. Epilepsy Curr 2017; 17 (02) 91-92
  • 10 Geffrey AL, Pollack SF, Bruno PL, Thiele EA. Drug-drug interaction between clobazam and cannabidiol in children with refractory epilepsy. Epilepsia 2015; 56 (08) 1246-1251
  • 11 Stout SM, Cimino NM. Exogenous cannabinoids as substrates, inhibitors, and inducers of human drug metabolizing enzymes: a systematic review. Drug Metab Rev 2014; 46 (01) 86-95
  • 12 Morrison G, Crockett J, Blakey G, Sommerville K. A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects. Clin Pharmacol Drug Dev 2019; 00 (00) 1-23 ; Epub ahead of print
  • 13 Gaston TE, Bebin EM, Cutter GR, Liu Y, Szaflarski JP. ; UAB CBD Program. Interactions between cannabidiol and commonly used antiepileptic drugs. Epilepsia 2017; 58 (09) 1586-1592
  • 14 Ravaud A, Urva SR, Grosch K, Cheung WK, Anak O, Sellami DB. Relationship between everolimus exposure and safety and efficacy: meta-analysis of clinical trials in oncology. Eur J Cancer 2014; 50 (03) 486-495
  • 15 Franz DN, Lawson JA, Yapici Z. , et al. Everolimus dosing recommendations for tuberous sclerosis complex-associated refractory seizures. Epilepsia 2018; 59 (06) 1188-1197